

**TABLE 180: TREATMENT-EXPERIENCED SVR GENOTYPE 4 WITH PEARL-I STUDY ADDED: ODDS RATIOS, RELATIVE RISKS, AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	SOF12 + RBV12	1.42 (0.87 to -1.91)	26.15 (-8.41 to -44.97)
DCV24 + ASU24 + PR24		1.56 (1.22 to -2.03)	33.97 (14.58 to -48.90)
PAR/RIT12 + OMB12 + RBV12		1.60 (1.29 to -2.07)	36.23 (20.33 to -50.52)
DCV24 + ASU24 + PR24	SOF24 + RBV24	1.08 (0.87 to -1.76)	7.18 (-12.45 to -41.20)
PAR/RIT12 + OMB12 + RBV12		1.11 (0.94 to -1.79)	9.51 (-6.08 to -42.99)
PAR/RIT12 + OMB12 + RBV12	DCV24 + ASU24 + PR24	1.02 (0.90 to -1.23)	1.86 (-9.40 to -18.32)
Random effect model	Residual deviance	5.834 vs. 6 data points	
	Deviance information criteria	28.416	
Fixed effect model	Residual deviance	5.796 vs. 6 data points	
	Deviance information criteria	28.342	

Cri = credible interval; DCV = daclatasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RIT = ritonavir; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.